行情

INVA

INVA

Innoviva
NASDAQ

实时行情|Nasdaq Last Sale

15.07
+0.12
+0.80%
盘后: 15.07 0 0.00% 16:20 02/14 EST
开盘
14.95
昨收
14.95
最高
15.19
最低
14.91
成交量
110.31万
成交额
--
52周最高
16.29
52周最低
10.03
市值
15.26亿
市盈率(TTM)
10.87
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INVA 新闻

  • 沪指震荡下跌 A股投资者数量首次突破1.6亿
  • 新浪财经.1小时前
  • 三星为应对疫情减少实体营销 快递送手机供用户体验
  • 新浪财经.1小时前
  • 港股异动 | 小米集团盘中异动,股价一度跌超4%
  • 华盛通.2小时前
  • 韩国总统称经济处于经济状态 需全力以赴刺激内需
  • 新浪财经.2小时前

更多

所属板块

制药
-0.16%
制药与医学研究
-0.16%

热门股票

名称
价格
涨跌幅

INVA 简况

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
展开

Webull提供Innoviva Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。